Gastrointestinal Cancer | Norton Healthcare

Indication: Gastrointestinal Cancer

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangement

Sub-indication: Gastrointestinal Cancer

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Taiho Oncology, Inc

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.